Johnson & Johnson (JNJ)
162.84
+0.03 (0.02%)
Johnson & Johnson is a multinational corporation engaged in the development, manufacturing, and marketing of a wide range of healthcare products
The company operates through three primary segments: pharmaceuticals, medical devices, and consumer health products. Johnson & Johnson is known for its commitment to innovation in healthcare, producing a diverse array of products that include prescription medications for various diseases, sophisticated medical devices for surgical procedures, and widely recognized consumer brands for personal care and wellness. With a focus on improving health outcomes, the company aims to address the evolving needs of patients and consumers around the world.

Amazing deals abound within Wall Street's benchmark index.
Via The Motley Fool · March 17, 2025

Large-cap stocks worst performers last week: TER, TTD, COIN, SAIL, GMAB, IBKR, DAL, ADBE, EXPE, HOOD, UAL, AAPL. Are they in your portfolio?
Via Benzinga · March 16, 2025

A lawsuit has been lodged against JPMorgan Chase by its employees, who claim that the company's prescription drug plan consented to pay exorbitant prices for medications.
Via Benzinga · March 15, 2025

Via Benzinga · March 10, 2025

Via Benzinga · March 5, 2025

Via The Motley Fool · March 14, 2025

Via The Motley Fool · March 14, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at branded pharmaceuticals stocks, starting with Supernus Pharmaceuticals (NASDAQSUPN).
Via StockStory · March 14, 2025

When selecting dividend-paying stocks, one of the first things that investors look at is, of course, the annual yield. But are high-yield stocks always the best route for income-focused investors? Let’s break it down.
Via Talk Markets · March 11, 2025

Via The Motley Fool · March 10, 2025

Vanguard has some excellent dividend ETFs, but they are right for different investors.
Via The Motley Fool · March 11, 2025

The company is looking to take on Bristol Myers Squibb's Sotyktu in plaque psoriasis treatment.
Via Investor's Business Daily · March 10, 2025

Via Benzinga · March 10, 2025

Protagonist and Johnson & Johnson's treatment for ulcerative colitis and psoriasis studies met key endpoints.
Via Benzinga · March 10, 2025

Via Benzinga · March 10, 2025

The market has thrown a tantrum over recent weeks following tariff news and other economic data pointing to a slowing consumer base. While it’s certainly been a turbulent period, several stocks have been able to shake off these market woes.
Via Talk Markets · March 9, 2025

Johnson & Johnson discontinues aticaprant's Phase 3 trial but explores future options. Another depression drug Spravato sales hit $1.01 billion
Via Benzinga · March 7, 2025

Two of the Dow Jones Industrial Average's 30 components make for no-brainer buys, while another brand-name member continues to suffer from self-inflicted wounds.
Via The Motley Fool · March 6, 2025

These ETFs have outperformed the market so far in 2025 but have lower asset bases than some of the most popular funds among investors.
Via MarketBeat · March 6, 2025

HC Wainwright initiates coverage on ImmunityBio with a Buy rating, citing Anktiva's growth potential. The firm projects $4.3 billion in sales, up from $137M in 2025.
Via Benzinga · March 6, 2025

Berkshire's cash hoard is approaching "Dr. Evil" levels.
Via The Motley Fool · March 3, 2025

Via The Motley Fool · March 3, 2025

U.S. markets suffered a steep selloff Monday as President Donald Trump announced sweeping new tariffs, extending last week's losses and driving declines across all major sectors.
Via Benzinga · March 4, 2025